How the hip injection is delivered

ChondroFiller™ is not a surgical procedure. The entire treatment takes place in an outpatient clinic — no general anaesthetic, no theatre admission, and no incision.

At the appointment, a local anaesthetic is administered around the hip joint to minimise discomfort. Professor Paul Lee then uses real-time ultrasound guidance to position the needle precisely within the focal cartilage defect. Once the injectable collagen scaffold is delivered, it hardens into a gel within three to five minutes and bonds immediately with the joint's natural fibrin, anchoring it in place without any stitches or wound care.

The mechanism is additive rather than subtractive. ChondroFiller™ lays a fresh layer of Type I collagen over the worn articular surface, acting as a viscoelastic cushion — no existing tissue is removed or debrided. Over time, the scaffold recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone, a process known as acellular matrix-induced chondrogenesis. This is distinct from cartilage regrowth in any guaranteed sense; the extent of biological response varies between individuals.

The treatment targets focal Grade III/IV articular cartilage defects in the hip joint. Whether it is appropriate for a given patient depends on imaging findings, joint mechanics, and an individual assessment with Professor Lee at the Grantham or Sleaford clinic.

The first 48–72 hours after injection

Some hip discomfort after any intra-articular injection is expected — this is not a sign that something has gone wrong. Once the local anaesthetic wears off, typically within a few hours of leaving the clinic, the hip joint may feel sore, mildly swollen, and stiffer than before the appointment. Discomfort usually peaks within the first 24–48 hours and then settles progressively over the following days.

Paracetamol or ibuprofen for the first two to three days is standard practice and sufficient for most people. Professor Lee's specific aftercare instructions should be followed closely, as individual guidance may vary.

During this initial window it is important to avoid strenuous hip loading. The collagen scaffold has only just begun to integrate, and early mechanical protection helps it stabilise in the joint environment. This does not mean strict bed rest — controlled, gentle movement is encouraged — but activities that place significant demand on the hip joint should wait.

IV antibiotic cover is included as standard in the Lincolnshire Hip package. Any signs of unusual warmth, persistent fever, or hip pain that continues to worsen beyond 72 hours rather than easing should prompt prompt contact with the clinic for assessment.

Limiting hip load in the first six weeks

For approximately the first six weeks, the priority shifts from the procedure itself to protecting the newly placed scaffold while it does its initial work. This is the Protect phase, and its logic is straightforward: the gelled collagen needs a period of reduced mechanical stress to stabilise, bond with the surrounding tissue, and begin recruiting the patient's own progenitor cells into its matrix. Loading the hip heavily too soon risks disrupting that early integration before it has taken hold.

In practice, this does not mean stopping movement altogether — maintained immobility risks stiffness that is counterproductive to recovery. Day-to-day walking at a comfortable pace is generally permitted, and controlled, low-demand movement through the hip joint is actively encouraged. What to avoid during this window includes high-impact activity (running, jumping), prolonged periods of standing, and any lifting that loads the hip under significant strain.

Because ChondroFiller™ at Lincolnshire Hip is delivered as an outpatient injection rather than through the surgical keyhole pathway, the Protect phase carries none of the operating-room or general-anaesthetic recovery burden. There are no surgical wounds and no hospital stay to manage; most patients can return home the same day and move around their own environment within sensible limits from the outset.

The exact duration of the Protect phase — and precisely when to progress — is determined by Professor Lee on an individual basis rather than by a fixed calendar. Factors such as defect size, joint condition, and how the hip is responding all inform the timing.

Physiotherapy and progressive return to activity

Physiotherapy typically begins somewhere between weeks four and six — when the scaffold has stabilised sufficiently to tolerate progressive loading — and continues through to around weeks eight to twelve. The precise start point is determined by how the hip is responding, not by a fixed date on the calendar.

The focus in this Strengthen phase is hip muscle function rather than general fitness. The hip abductors and external rotators play a particular role: stronger, better-coordinated muscles around the joint reduce the contact forces transmitted through the articular surface on every step. During the twelve-month window in which the cartilage defect is filling progressively, maintaining that muscular protection is meaningful — it helps avoid overloading the maturing repair tissue before it has the structural resilience to cope.

Low-impact activity typically comes first. Swimming and cycling are well suited to this period because they allow the hip to move through a useful range without the joint-impact forces associated with running or return to sport. Walking distance can be extended gradually as strength and confidence build.

Higher-impact activity, sport, and physically demanding work are reintroduced only when hip function — strength, stability, and pain response — supports it. Professor Lee and the treating physiotherapist determine that progression together; a functional milestone is a more reliable guide than a week number.

Patients consulting at the Grantham or Sleaford clinics can discuss local physiotherapy options at their six-week follow-up appointment.

Cartilage maturation over 12 months

The twelve months that follow the Protect and Strengthen phases are where the deeper biological work unfolds. Once the collagen scaffold has stabilised and the patient's own progenitor cells have migrated into its matrix — a process that begins within days to weeks of injection — the cartilage defect fills progressively across the first year. By one to two years, the scaffold itself is fully resorbed and replaced by the patient's own tissue.

Structural MRI data from available outcome studies illustrate this trajectory clearly. MOCART scores — a validated measure of cartilage repair quality on MRI — rise from approximately 65 at four weeks to around 82 at twelve months, indicating greater than 80% defect filling and progressive tissue integration over that period. Functional improvement follows a similar arc: in published multi-joint series, mean gains in validated patient-reported function scores of approximately 30 points have been reported at three-year follow-up, well above the threshold considered clinically meaningful. That sustained gain reflects the biological mechanism — acellular matrix-induced chondrogenesis, in which the scaffold supports the body's own repair processes rather than delivering a one-off chemical effect.

It is worth noting that these figures derive principally from studies encompassing knee and other joint defects; hip-specific published data for the injectable route are limited, and improvement trajectories in the hip should be treated as approximate guidance rather than fixed benchmarks.

For patients at Lincolnshire Hip, a six-week follow-up with Professor Lee is included in the standard package. Where clinically indicated, MRI can be arranged thereafter to track structural progress across that twelve-month window.

ChondroFiller at Lincolnshire Hip

Patients across Lincolnshire and the wider East Midlands can access ChondroFiller assessment locally, without travelling to London. Initial consultations take place at clinics in Grantham and Sleaford; the injection itself is delivered at a private facility equipped for image-guided outpatient treatment.

The pathway is led by Professor Paul Y.F. Lee, the first clinician in the UK to administer ChondroFiller® as a hip injection rather than a surgical implant. The standard package — priced at £2,995 — covers consultation, real-time ultrasound guidance, the ChondroFiller scaffold product, IV antibiotic cover, and a six-week post-injection review.

There is no age cut-off for assessment. Patients who have been told they are 'bone on bone' are not automatically excluded; suitability depends on the cartilage defect pattern, joint mechanics, and individual treatment goals, all of which Professor Lee reviews directly.

ChondroFiller sits within a full hip pathway that also includes Arthrosamid, PRP, and hip replacement. The most appropriate option — or combination — is matched to each patient's clinical picture rather than applied as a default.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.